1. Home
  2. WOOF vs OBX Comparison

WOOF vs OBX Comparison

Compare WOOF & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Petco Health and Wellness Company Inc.

WOOF

Petco Health and Wellness Company Inc.

N/A

Current Price

$2.45

Market Cap

713.2M

ML Signal

N/A

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$12.02

Market Cap

848.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WOOF
OBX
Founded
1965
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.2M
848.8M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
WOOF
OBX
Price
$2.45
$12.02
Analyst Decision
Hold
Strong Buy
Analyst Count
12
5
Target Price
$3.47
★ $38.67
AVG Volume (30 Days)
★ 3.6M
541.6K
Earning Date
12-08-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 108.11
N/A
EPS
★ 0.08
N/A
Revenue
★ $5,961,467,000.00
N/A
Revenue This Year
$0.46
N/A
Revenue Next Year
$1.23
N/A
P/E Ratio
$30.88
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.14
$9.60
52 Week High
$3.78
$39.00

Technical Indicators

Market Signals
Indicator
WOOF
OBX
Relative Strength Index (RSI) 40.01 42.10
Support Level $2.21 $11.84
Resistance Level $2.51 $15.87
Average True Range (ATR) 0.17 1.60
MACD -0.06 -0.03
Stochastic Oscillator 2.76 43.34

Price Performance

Historical Comparison
WOOF
OBX

About WOOF Petco Health and Wellness Company Inc.

Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: